secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0000950170-24-135822
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud

Akari Therapeutics: Interim CFO Wendy DiCicco departs; CEO Samir Patel assumes interim PFO/PAO roles
--------------------------------------------------------------------------------

- Wendy DiCicco's consulting agreement terminated on December 6, 2024, ending her role as Interim CFO, PFO, and PAO.
- Samir Patel, Interim CEO, appointed as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.
- Board initiated search for a new Chief Financial Officer.
- Separation terms for DiCicco are being finalized and will be disclosed in a subsequent filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024135822/0000950170-24-135822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024135822/aktx-20241206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer